卒中前二甲双胍使用与卒中严重程度及溶栓结局的关联
该多中心探索性分析纳入1919例接受静脉溶栓的2型糖尿病缺血性卒中患者,其中757例卒中前使用二甲双胍。经倾向性评分匹配后,二甲双胍组入院时卒中严重程度更低、3个月功能独立程度更好且死亡率更低,症状性颅内出血无差异。
要点
- 卒中前使用二甲双胍的糖尿病患者接受静脉溶栓后入院卒中严重程度更低。
- 二甲双胍组3个月功能结局更优且死亡率更低,症状性颅内出血无差异。
- 结果提示二甲双胍可能对卒中严重程度和溶栓结局具有保护作用。
核心结论
- 接受静脉溶栓的2型糖尿病卒中患者中,卒中前使用二甲双胍与入院时卒中严重程度更低及3个月功能结局更好相关。
研究设计与样本
- 欧洲TRISP协作组的多中心探索性分析,纳入1919例接受静脉溶栓的2型糖尿病缺血性卒中患者,并采用倾向性评分匹配平衡基线特征。
主要发现
- 1919例中757例(39%)卒中前使用二甲双胍,1162例(61%)未使用。
- 倾向性评分匹配后,二甲双胍组入院NIHSS为10.0±6.7,未使用组为11.3±6.5。
- 匹配后二甲双胍组3个月改良Rankin量表为2(IQR 1.0-4.0),未使用组为3(IQR 1.0-4.0)。
- 匹配后二甲双胍组死亡率为12.5%,未使用组为18%。
- 两组症状性颅内出血频率无差异,HbA1c水平均衡。
临床怎么用
- 对于接受静脉溶栓的2型糖尿病缺血性卒中患者,卒中前二甲双胍使用史可作为提示卒中严重程度较低和功能结局较好的参考信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate whether pretreatment with metformin (MET) is associated with less stroke severity and better outcome after IV thrombolysis (IVT), we analyzed a cohort of 1,919 patients with stroke with type 2 diabetes mellitus in a multicenter exploratory analysis. METHODS: Data from patients with diabetes and ischemic stroke treated with IVT were collected within the European Thrombolysis in Ischemic Stroke Patients (TRISP) collaboration. We applied propensity score matching (PSM) to obtain balanced baseline characteristics of patients treated with and without MET. RESULTS: Of 1,919 patients with stroke with type 2 diabetes who underwent IVT, 757 (39%) had received MET before stroke (MET+), whereas 1,162 (61%) had not (MET-). MET+ patients were younger with a male preponderance. Hypercholesterolemia and pretreatment with statins, antiplatelets, or antihypertensives were more common in the MET+ group. After PSM, the 2 groups were well balanced with respect to demographic and clinical aspects. Stroke severity on admission (NIH Stroke Scale 10.0 ± 6.7 vs 11.3 ± 6.5), 3-month degree of independence on modified Rankin Scale (2 [interquartile range (IQR) 1.0-4.0] vs 3 [IQR 1.0-4.0]), as well as mortality (12.5% vs 18%) were significantly lower in the MET+ group. The frequency of symptomatic intracerebral hemorrhages did not differ between groups. HbA1c levels were well-balanced between the groups. CONCLUSIONS: Patients with stroke and diabetes on treatment with MET receiving IVT had less severe strokes on admission and a better functional outcome at 3 months. This suggests a protective effect of MET resulting in less severe strokes as well as beneficial thrombolysis outcome.
引用
- Westphal LP, Widmer R, Held U, et al. Association of prestroke metformin use, stroke severity, and thrombolysis outcome. Neurology. 2020. PMID: 32601121. doi:10.1212/WNL.0000000000009951
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。